646 - Subgroup Analyses of Microbiological Cure Rates by Baseline Zoliflodacin MIC and Susceptibility to Ciprofloxacin in Participants from the Global Zoliflodacin Phase 3 Randomized Controlled Trial

Presenting Author(s)

• SM

  Sarah McLeod, PhD (she/her/hers)

  Senior Director
  Innoviva Specialty Therapeutics, Inc.
  Waltham, MA, United States

  Slides

Co-Author(s)

• EB

  Esther Bettiol, MD PhD

  Senior Clinical Scientist
  Global Antibiotic R&D Partnership
  Geneva, Geneve, Switzerland
• VE

  Varalakshmi Elango, MD

  Consultant Microbiologist
  Global Antibiotic R&D Partnership
  Chennai, Tamil Nadu, India
• KR

  Khurram Rana, PharmD

  Sr. Director
  Innoviva Specialty Therapeutics
  Madison, Connecticut, United States
• DL

  Drew Lewis, MD, MTM&H, FACP

  Vice President
  Innoviva Specialty Therapeutics
  Waltham, Massachusetts, United States
• AL

  Alison Luckey, MD

  Global Antibiotic R&D Partnership (GARDP)
  Geneva, Geneve, Switzerland